# Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis

> **NIH NIH R01** · UNIVERSITY OF CHICAGO · 2023 · $582,022

## Abstract

PROJECT SUMMARY
Mycobacterium tuberculosis (Mtb) latently infects one-fourth of the world’s population, causing pulmonary
tuberculosis (TB) in ~10 million people and resulting in ~1.5 million deaths each year. The currently
available TB vaccine, Mycobacterium bovis BCG (BCG), shows variable efficacy. In addition, Multi-Drug-
Resistant (MDR) Mtb strains have recently emerged. Thus, there is a great need for new TB vaccines.
Studies in the past decade have mainly utilized induction of T helper cell type 1 (Th1) responses and the
production of the cytokine, Interferon-gamma (IFNγ), as readout for vaccine efficacy against TB. Our
studies during the prior funding period demonstrated that Interleukin (IL)-17 and T helper type 17 (Th17)
vaccine responses are critical for vaccine-induced immunity against TB. Importantly, we recently
demonstrated that mucosal vaccination with the Mtb antigen with Th17-inducing adjuvants induced potent
lung-resident Th17 cells and improved BCG vaccine-induced protection following Mtb challenge. Our
mechanistic studies demonstrated that IL-17-induced chemokines, including CXCL-13, localize CXCR5-
expressing T cells near Mtb-infected macrophages, resulting in the formation of lung lymphoid follicles and
activating macrophages to mediate Mtb control. Despite these major advances in understanding the role of
Th17 vaccine-induced cells in TB, our data show that upon Mtb infection, the accumulation of vaccine-
induced Th17 immune responses in the lung is not accelerated enough to provide “sterilizing” immunity or
complete Mtb control. In exciting new data generated during the prior funding cycle, we show that we can
overcome this bottleneck by using Dendritic Cell (DC) based therapy by either activating endogenous DCs,
or transfer of exogenously activated DCs into vaccinated hosts, to achieve superior Mtb control. Thus, the
work proposed in this R01 renewal builds on these important and highly relevant findings with three
Specific Aims: Specific Aim 1. Identifying the early cytokine pathways that modulate APC function to
promote Th17 responses and induce superior immunity against TB. Specific Aim 2. Identifying the IL-23
and IL-17-dependent mechanisms that mediate early Th17 responses and Mtb control. Specific Aim 3.
Identification of novel C-type lectin receptor agonists as Th17-inducing TB vaccines. The emergence of
extensively drug-resistant strains (XDR) of Mtb, for which no treatments currently exist, makes the
development of an effective TB vaccine incredibly urgent. The work proposed in this grant will continue to
significantly impact the design and use of future vaccine strategies by allowing us to promote IL-17
responses to generate improved, long-term lasting vaccine-induced immunity against TB.

## Key facts

- **NIH application ID:** 10841309
- **Project number:** 5R01HL105427-12
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** Shabaana A. Khader
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $582,022
- **Award type:** 5
- **Project period:** 2010-12-15 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10841309

## Citation

> US National Institutes of Health, RePORTER application 10841309, Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis (5R01HL105427-12). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10841309. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*